



FDA extends shelf life of COVID antiviral Paxlovid

April 7, 2022

Melissa Jenco, News Content Editor

Article type: [News](#)

Topics: [COVID-19](#), [Infectious Diseases](#), [Pharmacology](#)

Editor's note: For the latest news on COVID-19, visit <http://bit.ly/AAPNewsCOVID19>.

The shelf life of some lots of COVID-19 antiviral Paxlovid has been extended from nine months to 12 months.

The Food and Drug Administration (FDA) authorized the change for certain lots if they have been stored properly.

Lots FL4516, FL4517 and FR7229 with an expiration date of July 31, 2022, can be used through Oct. 31, 2022. Lot FR9088 with an expiration date of Aug. 31, 2022, can be used through Nov. 30, 2022.

Paxlovid from Pfizer is a combination of nirmatrelvir and ritonavir. The FDA granted emergency use authorization of the antiviral to treat non-hospitalized people ages 12 years and older weighing at least 40 kilograms with mild to moderate COVID-19 who are [at risk of progressing to severe disease](#).

Serious adverse events and medication errors potentially related to Paxlovid must be reported to the [FDA's MedWatch program](#).

Resources

- [AAP interim guidance *Management Strategies in Children and Adolescents with Mild to Moderate COVID-19*](#)
- [Paxlovid fact sheet for health care providers](#)
- [Information from Pfizer about Paxlovid](#)

- [National Institutes of Health COVID-19 treatment guidelines](#)

Copyright © 2022 American Academy of Pediatrics